Flow Visualization of Thrust-Vectoring Lightcraft Engines with ∼1μs Pulsed TEA CO[sub 2] Laser

Autor: D. A. Kenoyer, I. I. Salvador, S. N. Notaro, L. N. Myrabo, Hans-Albert Eckel, Stefan Scharring

Publikováno v: AIP Conference Proceedings.

The thrust‐vectoring performance of four laser propulsion engine geometries were visualized using a twin Lumonics K922M pulsed TEA CO2 laser system, with a Cordin® high speed digital camera and Schlieren photography. Airbreathing mode engines were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::78ffa1730383f1f72181da806a523a07
https://doi.org/10.1063/1.3657020

Development of Surface Junction Thermocouples for High Enthalpy Measurements

Autor: P. G. P. Toro, A. C. Oliveira, M. A. S. Minucci, I. I. Salvador, J. B. Channes

Publikováno v: AIP Conference Proceedings.

Among the fundamental data needed to be acquired in hypersonic experiments with energy deposition to the flow are the heat transfer rates to the model. Such task is not easily accomplished though, due to several factors relative to flow characteristi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa87cc577ab39b1e21b0f8651299b61e
https://doi.org/10.1063/1.2203290

Experimental Analysis of Heat Flux to a Blunt Body in Hypersonic Flow with Upstream Laser Energy Deposition — Preliminary Results

Autor: A. C. Oliveira, H. T. Nagamatsu, J. B. Channes, M. A. S. Minucci, P. G. P. Toro, I. I. Salvador, L. N. Myrabo

Publikováno v: AIP Conference Proceedings.

Due to high heat transfer rates in hypersonic flight and its consequent necessity of prohibitively massive thermal protection system, new methods of flow control are required to enable flight in such regimes. Here arises the Direct Energy Air Spike c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2e236e6c26ff22a74ae7a40fe374f12
https://doi.org/10.1063/1.2203258

Patterns and outcomes of switching direct oral anticoagulants in non-valvular atrial fibrillation: A real-world experience from Spain.

Autor: Rodilla E; Internal Medicine Department, Hypertension and Vascular Risk Unit, Hospital Universitario de Sagunto, Department of Medicine, Valencia, Spain; Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. Electronic address: rodilla_enr@gva.es., Orts-Martínez MI; Internal Medicine Department, Hematology, Hospital Universitario de Sagunto, Spain., Sanz-Caballer MA; Internal Medicine Department, Hematology, Hospital Universitario de Sagunto, Spain., Gimeno-Brosel MT; Internal Medicine Department, Hematology, Hospital Universitario de Sagunto, Spain., Arilla-Morel MJ; Internal Medicine Department, Hematology, Hospital Universitario de Sagunto, Spain., Navarro-Gonzalo I; Internal Medicine Department, Hematology, Hospital Universitario de Sagunto, Spain., Castillo-Valero I; Internal Medicine Department, Hematology, Hospital Universitario de Sagunto, Spain., Salvador-Mercader I; Internal Medicine Department, Cardiology, Hospital Universitario de Sagunto, Spain., Carral-Tatay A; Internal Medicine Department, Hematology, Hospital Universitario de Sagunto, Spain.

Publikováno v: Revista clinica espanola [Rev Clin Esp (Barc)] 2023 Jun-Jul; Vol. 223 (6), pp. 340-349. Date of Electronic Publication: 2023 Apr 25.

A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.

Autor: Moreno-González G; Intensive Care Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain. gabriel.moreno@bellvitgehospital.cat.; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain. gabriel.moreno@bellvitgehospital.cat., Mussetti A; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Clinical Hematology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., Albasanz-Puig A; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.; Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain., Salvador I; Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain., Sureda A; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Clinical Hematology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.; Barcelona University, Barcelona, Spain., Gudiol C; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.; Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain.; Barcelona University, Barcelona, Spain., Salazar R; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Clinical Oncology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., Marin M; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Clinical Oncology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., Garcia M; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Clinical Trials Unit, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., Navarro V; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Clinical Trials Unit, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., de la Haba Vaca I; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Oncology Emergency Unit, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., Coma E; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Oncology Emergency Unit, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., Sanz-Linares G; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Clinical Hematology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., Dura X; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain., Fontanals S; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Pharmacology Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., Serrano G; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Palliative Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., Cruz C; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.; Palliative Department, Institut Català d' Oncologia, L'Hospitalet de LL., Barcelona, Spain., Mañez R; Intensive Care Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.

Publikováno v: Trials [Trials] 2021 Feb 05; Vol. 22 (1), pp. 116. Date of Electronic Publication: 2021 Feb 05.